SMi are proud to present Pharmaceutical Nanotechnology: Applications & Commercialisation, taking place in London on June 29th and 30th, 2011. Nanotechnology is a multidisciplinary scientific field that is currently undergoing undergoing explosive development. Nano-enhanced medicines are opening new opportunities for therapeutic delivery and targeting, technology is also allowing agents that previously could not be used effectively as conventional formulations due to poor bioavailability or drug instability to advance into clinical development. This case study driven conference will address not only the latest scientific developments, but also the know-how required to successfully translate these discoveries and technologies into a commercially successful product.

1. Pharmaceutical Nanotechnology:
Applications & Commercialisation
SMi presents…
Wednesday 29th & Thursday 30th June 2011
Copthorne Tara Hotel, London
REGISTER BY 28th FEBRUARY AND RECEIVE A £300 DISCOUNT
REGISTER BY 31st MARCH AND RECEIVE A £100 DISCOUNT
KEY SPEAKERS INCLUDE:
Thomas Keller
Director, Open Innovation
GlaxoSmithKline
Sergey Pechenov
Research Fellow, Parenteral Formulation Development
Merck
This case study driven
Mike Eaton
conference will address not
Executive Board Member
European Technology Platform on Nanomedicines
only the latest scientific
Molly Stevens
developments and their
Research Director for Biomedical Materials
Imperial College London
implementations, but also the
know-how required to
Jens Uhlemann
Head of CC Product Design & Nanotechnology
Bayer
successfully translate these
discoveries and technologies
Peter Luke
into a commercially successful
Senior Director, R&D Business Development
Pfizer
product.
PLUS AN INTERACTIVE POST–CONFERENCE WORKSHOP
BY ATTENDING YOU WILL BE ABLE TO:
Nanomedicines: Regulatory Challenges and Opportunities
• Hear the latest technology and process developments
• Discover the challenges, opportunities and risks ahead
• Compare the available technologies and selecting the best option for
your project
www.pharma-nanotech.co.uk
• Case studies addressing the translation of academic research to
commercial success
Friday 1st July 2011, Copthorne Tara Hotel, London
• Network with key industry leaders and identify partnering opportunities
Hosted by Brian Kelly, Regulatory Lawyer, Covington & Burling LLP &
Simon Holland, Director, Process Understanding & Control, GlaxoSmithKline
8.30am - 1.00pm
Register online and receive full information on all of SMi’s conferences
Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

2. www.pharma-
Pharmaceutical Nanotechnology
Day One Wednesday 29th June 2011
8.30 Registration & Coffee 12.35 Networking Lunch
9.00 Chairman's Opening Remarks 1.35 New nanomaterials for regenerative medicine
Mike Eaton, Executive Board Member, European Technology Platform
• Taking tissue engineering products from bench to bedside
on Nanomedicines
• Materials based approaches for regenerative medicine
STRATEGIC OVERVIEW • Design of nanomaterial scaffolds for tissue regeneration
• Translation to commercial products and clinical studies
KEYNOTE ADDRESS: Molly Stevens, Research Director for Biomedical Materials, Imperial
9.10 Pharmaceutical applications of nanoparticles College London
• Pharmaceutically relevant nanoparticles within the nanotechnology
landscape
• Nanoparticle formulations for bio-efficacy enhancement and for NANO-ENABLED NUCLEIC ACID THERAPEUTIC DELIVERY
controlled release
• Nanoparticle formulations for biopharmaceuticals delivery 2.10 Delivering siRNA therapeutics
• Progress to Date, general issues / obstacles and some solutions Promises, results and challenges of nanotechnology
Jens Uhlemann, Head of CC Product Design & Nanotechnology, • Technology and therapeutic updates
Bayer
• Pros and cons of RNAi delivery methods
ENGINEERING, FORMULATION & DRUG DELIVERY • Case study: Lipid nanoparticle–mediated systemic delivery of siRNA
to the liver
KEYNOTE ADDRESS: Sergey Pechenov, Research Fellow, Parenteral Formulation
9.45 Nanoscale drug delivery systems Development, Merck
Comparing available technologies and selecting the best option for
your project
KEYNOTE ADDRESS:
• Role of nanotechnology in targeted drug delivery
• Evaluating the available technologies 2.45 Oligonucleotide delivery & formulation
• Performance and safety issues Delivery systems for immunostimulatory oligonucleotide agonists
• Case study: The development of biodegradable nanoscale drug • Overview
delivery systems at Novartis • Case study: Project & data
• Looking ahead to future steps in pharmaceutical development • Looking ahead to the future
Giancarlo Francese, Project Leader Pharmaceutical Development,
Amina Benahmed, Associate Director Nucleic Acid Delivery,
Novartis
Coley Pharmaceuticals – A Pfizer Company
10.20 Morning Coffee
3.20 Afternoon Tea
10.50 Miniaturisation and modelling of beads milling
• Relevant information to get at lab scale in order to help the scale- 3.50 Investigation of chitosan nanoparticle formulations
ability
Biophysics, intracellular trafficking and structural features
• Is it possible to apply similar methodology to that developed for dry
Register online at www.pharma-nanotech.co.uk• Alternatively fax
milling-micronisation? • Impact of chitosan purity, size and source on nanoparticle formulation
• Impact of process parameters and formulation on milling • Biophysical characterization of chitosan/siRNA nanoparticles using
performances dynamic light scattering, zeta potential, isothermal titration calorimetry
Mostapha Nakach, Pharmaceutical Engineering, Sanofi Aventis • Cellular trafficking events of siRNA; the role of chitosan polymer size
• Structure/activity relationships between nanoparticles made of
11.25 Ten development criteria to cross barriers from blood-to-brain using
different chitosan polymer sizes
nanotechnology
• Success criteria based on: 1) safely targeting the blood-brain Michael Keller, Senior Fellow, siRNA Project Leader, Novartis
barrier; 2) use of validated drug carriers; 3) translation from lab to
clinic 4.25 Nanoparticles for the delivery of oligonucleotides targeting EWS/Fli-1
• Introduction to G-Technology Targeting cancer utilising polyalkycyanoacrylates and diamond
• Case study I: glutathione pegylated liposomal doxorubicin (2B3-101) nanoparticles
for brain cancer
• The prevalence of EWS/Fli-1 oncogene in Ewing sarcoma patients
• Case study II: pharma industry partnering model
Marco de Boer, Head of Research, to-BBB Technologies • The need to protect antisense oligonucleotides and siRNA until they
reach their EWS/Fli-1 mRNA target
12.00 Delivering peptides to the brain • Biodegradable and biocompatible polyalkylcyanoacrylate
• The challenge nanoparticles coated with chitozan
• Nanoparticle/ nanofibre technology • Developing cationic nanodiamond vectors and evaluating their
• Delivering peptides via the intravenous route
efficiency for anionic siRNA delivery
• Delivering peptides via the oral route
• Case study: Oral Enkephalin Claude Paul Malvy, Director, IFSBM, Université Paris-Sud
Ijeoma Uchegbu, Professor, Chair in Pharmaceutical Nanoscience,
University of London 5.00 Chairman's Closing Remarks and Close of Day One
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Prime
networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your
industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on
+44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Want to know how you can get involved?
Interested in promoting your pharmaceutical services to this market?
Contact Kiran Sharma, SMi Marketing on +44 (0) 207 827 6050, or email ksharma@smi-online.co.uk
Supported by

3. -nanotech.co.uk
Pharmaceutical Nanotechnology
Day Two Thursday 30th June 2011
8.30 Re-registration & Coffee REGULATORY CONSIDERATIONS, IP ISSUES
9.00 Chairman's Opening Remarks & PARTNERING OPPORTUNITIES
Thomas Keller, Director of Nanomaterials, GlaxoSmithKline
KEYNOTE ADDRESS: 2.00 Regulatory challenges for nanomedicines
9.10 The business case for nanotechnology Specific challenges for assessing nanomaterials within the
• Limitations and cost effectiveness comparisons
• Benchmarking and the need for agreed industry standard systems existing regulatory framework for medicines and against the
for evaluation
• Challenges in translational development general background of the precautionary principle
• Partnering strategies and opportunities • Borderline and classification issues
Thomas Keller, Director of Nanomaterials, GlaxoSmithKline
• Limitations of current testing methods
9.50 Enhancing industry-academia partnership in Pharmaceutical • Development, manufacture and characterisation
nanotechnology
Road to faster commercialisation • Risk management planning
• Tailor made innovation funnels
• Innovation Box for Implementation of Nanotech Tools (IBINT©) • Reimbursement
• Start-up companies : Bridging the gap between industry & • Public perception
academia
• Strategies to pick "low hanging fruits" to futuristic technologies • Lessons from other sectors
• Individual technologies versus a platform of technologies
Peter Bogaert, Managing Partner, Covington & Burling LLP
• Ability to connect seemingly unconnected dots
Challa Kumar, President & CEO, Magnano Technologies Brian Kelly, Associate, Covington & Burling LLP
10.30 Morning Coffee
2.40 Afternoon Tea
11.00 Enabling oncology drug development with nanotechnology
• Key challenges in oncology drug discovery
• Optimizing the discovery/development interface
3.20 A tour of today's Nanomedicine patent landscape: predicting
• Key technology platforms
• Taking a portfolio approach where the future IP battle lines will be drawn
• The Nanomedicines Alliance – a pre-competitive consortium for
cross-industry collaboration • The current patent landscape of nanotech-enabled
Henry Havel, Senior Research Fellow, Product Research and pharmaceutical applications
Development, Eli Lilly and Company
• The expectation that the commercialization of nanotech-enabled
TRANSLATING DISCOVERIES INTO COMMERCIAL SUCCESSES
pharmaceuticals will lead to patent battles of epic proportions
your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
11.40 Improving translation of academic nanomedicine research • Predictions of the most likely IP battlegrounds and of those who
• Companies are increasing relying on Open Innovation for new
products are battling
• Academic pharmaceutical research is not informed on the Jeffrey Rosedale, Partner, Woodcock Washburn
requirements for industrial development
• Funding agencies continue to fund non-translatable applied
research
KEYNOTE ADDRESS:
• There is now global competition
• How can the system be made much more productive? 3.50 Industry partnering opportunities, open innovation, one solution
Mike Eaton, Executive Board Member, European Technology
Platform on Nanomedicines • Open innovation- what does it mean for Pharma?
• Establishing effective alliances
12.20 Networking Lunch
• Public-private partnerships for more effective research
1.20 Building a diversified nanomedicine company
• Balancing diversification and focus • Lessons learnt and illustrative case studies
• Follow the science Peter Luke, Senior Director, R&D Business Development,
Who should attend:
• Models that maximize shots on goal
• Finding and relying on synergy Worldwide Business Development, Pfizer
• Case Study: Nanotope, Inc
Christopher Anzalone, President & CEO, Arrowhead Research
Corporation 4.30 Chairman's Closing Remarks and Close of Conference
CEOs, CSOs, VPs, Directors, Heads, Scientists and Academics focusing on:
• Analytical Chemistry • Drug Discovery • Physiochemistry • Regulatory Affairs
• Analytical Development • Formulation • Portfolio Management • Solid States
• Business Development • Lifecycle Management • Preclinical Development
• Toxicology
• Chemical Engineering • Licensing • Pre-Formulation
• Discovery R&D • Medicinal Chemistry • Process R&D
• Drug Delivery • Pharmaceutics • Product Development

4. RNAi, miRNA and siRNA
PLUS! SAVE THE DATE FOR THE CO-LOCATED
SMi present their 6th conference on…
Monday 27th and Tuesday 28th June 2011
Copthorne Tara Hotel, London
REGISTER BY 28th FEBRUARY AND RECEIVE A £300 DISCOUNT
REGISTER BY 31st MARCH AND RECEIVE A £100 DISCOUNT
KEY SPEAKERS INCLUDE:
Troels Koch
VP, Research Division
Santaris Pharma
RNAi is still a new and exciting
Rachel Meyers
area of pharmaceutical
Vice President, Research and RLD
Alnylam
development, but with far to go
Mike Webb
before its vast therapeutic
Head, API & Chemistry Analysis, UK
GSK
potential is fully utilised. This
Dmitry Samarsky
conference will showcase the
Vice President, Technology Development
RXi Pharmaceuticals
latest progress made ensuring
delegates leave fully informed
PLUS A HALF-DAY POST-CONFERENCE WORKSHOP
Atilla Seyhan
Head, RNAi and Compound Deliver & Screens
Pfizer
of industry developments.
BY ATTENDING YOU WILL BE ABLE TO:
Laura Sepp-Lorenzino
Senior Director and Department Lead – RNA therapeutics Delivery Biology
Merck & Co
Manipulating exons to treat disease
www.rnai-event.com
• Hear the latest in RNAi therapeutic progression
• Learn about the ways top companies are utilising RNAi potential
Wednesday 29th June 2011, Copthorne Tara, London
• Study cutting edge approaches at overcoming siRNA delivery issues
• Network with some of the most important industry experts working in RNAi
• Develop a sound strategy of development in response to industry cuts
Hosted by Giles Campion, Chief Medical Officer and Senior Vice-President R&D, Prosensa
Register online and receive full information on all of SMi’s conferences
8.30am-12.30pm
Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

5. HALF DAY POST-CONFERENCE WORKSHOP
Nanomedicines: Regulatory Challenges and Opportunities
Friday 1st July 2011
8.30am-1.00pm
Copthorne Tara Hotel, London
In association with:
Overview of workshop About the workshop leaders:
This workshop aims to give participants an understanding
nanopharmaceutical applications and regulatory considerations, Brian Kelly, Regulatory Lawyer, Covington & Burling
including an overview of the technology, development considerations, LLP
manufacturing, safety and pricing/reimbursement issues. For Brian Kelly is a regulatory lawyer in the London Life
example, many novel applications of medical nanotechnology will Sciences group, whose practice focuses on food and
span the regulatory boundaries between medicinal products, drug law, public and administrative proceedings,
including advanced therapy medicinal products, and medical devices.
European Union law and product liability and safety. He
Getting the regulatory classification right is crucial in developing and
has more than ten years of experience in regulatory matters having first
commercialising products as different sets of rules govern each
regime. There will be a focus on useful case studies and processes, worked as a journalist covering medical and healthcare regulatory news
providing a strong, practical take home message to attending before joining Covington. He has a particular interest in advising life
delegates. science companies on nanotechnology regulatory matters. Mr Kelly's
advice on general regulatory matters includes borderline
Upon completion of this workshop, attendees should be able to: determinations, tissue and stem cell regulation, adverse event and other
• Understand existing and potential nanotechnology-based reporting obligations, manufacturing controls, labeling and promotion,
applications pricing and reimbursement/procurement, product life cycle
• Understand the special aspects of nanomedicines: development, management and anti-bribery and corruption advice. He has also
manufacturing and characterisation advised on EU and national laws governing clinical research, data
• Identify the key regulatory challenges: borderline issues, protection, telemedicine/eHealth, and regulatory aspects of mergers and
classification, safety and pricing/reimbursement of innovative acquisitions, licensing, and collaborative arrangements. He is an
nanomedicines honorary lecturer at University College London. www.cov.com
• Understand public perception and ethical considerations that
apply to nanopharmaceuticals Simon Holland, Director, Process Understanding &
Control, GlaxoSmithKline
8.30 Registration & Coffee Simon has worked in the pharmaceutical industry for
over 20 years and is an expert in the field of nanoparticle
9.00 Welcome & Introductions
manufacture. He studied chemistry at Bradford
• Experience and backgrounds of participants and hosts
• Purpose and scope of the workshop University (UK) followed by a PhD in polymer chemistry
at Aston University (UK). He joined Beecham
PHARMACEUTICAL FORWARD PLANNER
9.10 Nanopharmaceuticals on the market and in Pharmaceuticals, Worthing (UK) in 1986 and worked on the formulation
clinical development development of topical and penicillin drug products. After the merger
9.50 Development, manufacturing and characterisation of that formed SmithKline Beecham, Simon worked on the development of
nanomedicines neurosciences drug products and has focussed on the development of
10.30 Morning Coffee bioenhanced formulations for the past 13 years including with a
particular emphasis on sub micron compositions. He was the R&D lead
11.00 Regulatory challenges: borderline issues, safety and on the commercial scale nanomilling facility project that was opened at
other legal and ethical issues GSK Cork (Eire) in 2004. www.gsk.com
11.50 Pricing/reimbursement of innovative nanomedicines
12.10 Interactions with regulators over nanomedicine issues
• Manufacturing licenses
• Borderline determinations
• Clinical trials
12.40 Interactive Discussion Session
1.00 Close of Workshop
FEBRUARY 2011 JUNE 2011
07/08 Parallel Trade 01/02 Pain Therapeutics
ABOUT THE SMi PHARMACEUTICAL TEAM
21/22 Advances & Progress in Drug Design 27/28 RNAi
SMi have been involved in the pharmaceutical
23/24 Stem Cells 29/30 Nanotechnology
industry since 1993 and have developed a
29/30 Pharmaceutical Portfolio &
series of informative and niche events,
MARCH 2011 Product Lifecycle
covering the latest issues and developments
07/08 Imaging in Cancer Drug Development Management
surrounding the industry. Events bring
14/15 Pharmacovigilance 29/30 KOL Europe (Munich,
together senior industry professionals and
16/17 Superbugs & Superdrugs Germany)
serving companies who have a focus on being
23/24 Accelerating patient recruitment &
at the forefront of developments in this area.
Retention in Clinical Trials JULY 2011
SMi aim to generate informed and topical
30/31 Controlled Release 06/07 ADMET
discussion through the medium of both
11/12 BioBanking
conferences and executive briefings. Our
APRIL 2011 11/12 Social Media in the
pharmaceutical events are research-based
13/14 Asthma & COPD Pharmaceutical
and content driven with regular contact with
Industry
major industry personnel and cover a wide
MAY2011 18/19 Clinical Trial Logistics Asia
range of industry sectors.
11/12 Generics, Supergenerics and Patent (Singapore)
For more information, please visit
Strategies 20/21 Pre-Filled Syringes Asia
www.smionline.co.uk/pharma
16/17 Clinical Trial Logistics (Singapore)
All conferences take place in central London, UK
– unless indicated otherwise in brackets

6. PHARMACEUTICAL NANOTECHNOLOGY:
4 WAYS TO REGISTER
www.pharma-nanotech.co.uk
FAX your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, Great Guildford
PHONE on +44 (0) 870 9090 711
CONFERENCE PRICES
Conference: Wednesday 29th & Thursday 30th June 2011, Copthorne Tara Hotel, London, UK Workshop: Friday 1st July 2011, London
EARLY BIRD □ Book by 28th February to receive a £300 off the conference
Business Square, 30 Great Guildford Street London, SE1 0HS, UK
DISCOUNT □ Book by 31st March to receive a £100 off the conference
DELEGATE DETAILS
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & Half Day Workshop £1998.00 + VAT £2397.60
□ Conference only £1399.00 + VAT £1678.80
□ Half Day Workshop only £599.00 + VAT £718.80
VENUE
PROMOTIONAL LITERATURE DISTRIBUTION
Unique Reference Number
□ Distribution of your company’s promotional
Our Reference LVY17
GROUP DISCOUNTS AVAILABLE
literature to all conference attendees £999.00 + VAT £1198.80
CD ROMS/DOCUMENTATION
Title: Forename:
Surname:
The Conference fee includes refreshments, lunch, conference papers and
Job Title:
CD ROM containing all of the presentations.
Department/Division:
□ Please contact me to book my hotel
Company/Organisation:
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SR
Email:
PAYMENT
Address:
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
I cannot attend but would like to purchase the following CD ROMs/paper copy
documentation: (Shipped 10-14 days after the event) Price Total
Mobile:
□ The Conference Presentations on CD ROM £499.00 + VAT £598.80
Switchboard:
□ The Conference Presentations - paper copy £499.00 - £499.00
Terms and Conditions of Booking
(or only £300 if ordered with a CD ROM)
Signature: Date:
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Payment must be made to SMi Group Ltd, and received before the event, by one of the
I agree to be bound by SMi's Terms and Conditions of Booking.
Address (if different from above): following methods quoting reference Y17 and the delegate’s name. Bookings made within 7
days of the event require payment on booking, methods of payment are below. Please
indicate method of payment:
Valid From □□/□□ Expiry Date □□/□□
Town/City: □ UK BACS Sort Code 300009, Account 00936418
Post/Zip Code: Country: □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
Direct Tel: Direct Fax:
IBAN GB48 LOYD 3000 0900 9364 18
VAT
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
Card No:
All credit card payments will be subject to standard credit card charges.
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
Card Billing Address (If different from above):
I agree to be bound by SMi's Terms and Conditions of Booking.
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on CD
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
ROMs and Literature Distribution for all UK customers and for those EU customers not
supplying a registration number for their own country here: _______________________
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit card
details will be requested and payment taken before entry to the event. Bookings within 7 days of
□□□□ □□□□ □□□□ □□□□
event require payment on booking. CD Roms will not be dispatched until payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the Conference
documentation on CD ROM to any delegate who has paid but is unable to attend for any reason. Due
to the interactive nature of the Briefings we are not normally able to provide documentation in these
circumstances. We cannot accept cancellations of orders placed for Documentation or CD ROM as
these are reproduced specifically to order. If we have to cancel the event for any reason, then we will
make a full refund immediately, but disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act
1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our
website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.